Core Viewpoint - The pharmacy department in hospitals has undergone significant changes, shifting from a profit center to a cost center and now to a department focused on compliance with various drug-related assessments and regulations [2][30]. Group 1: Changes in Pharmacy Department's Role - The pharmacy department was once a key profit center for hospitals but transformed into a cost center after the cancellation of drug markups in public hospitals in 2017 [2][30]. - The department now faces a multitude of drug-related assessment indicators, such as antibiotic usage intensity and basic drug ratio, complicating its operational landscape [3][4]. - The pharmacy department's responsibilities have expanded to include compliance with both clinical needs and regulatory requirements, creating a complex work environment [4][6]. Group 2: Challenges Faced by Pharmacy Departments - Pharmacy department heads, like Wang Jun, report feeling overwhelmed by the increasing number of policies and assessments they must navigate, often leading to conflicts between clinical needs and regulatory demands [6][9]. - Issues such as drug shortages, particularly for commonly used medications, have become a frequent challenge, leading to patient complaints and added pressure from hospital administration [8][9]. - The pharmacy department must balance various conflicting demands from regulatory bodies, clinical staff, and patients, making their role increasingly complex [17][19]. Group 3: Evolving Assessment Metrics - The performance assessment metrics for pharmacy departments have become more detailed and stringent, with a focus on antibiotic usage and cost management [14][15]. - The introduction of new metrics, such as the average drug cost per outpatient/inpatient, has added to the pressure on pharmacy departments to manage costs effectively while ensuring compliance [15][22]. - The shift in focus from drug ratios to cost metrics reflects a broader trend in healthcare towards more comprehensive performance evaluations [15][22]. Group 4: Future Implications - The pharmacy department's role is evolving from a cost center to a compliance support function, emphasizing the need for effective communication and professional knowledge to navigate complex regulations [26][30]. - As the healthcare landscape continues to change, pharmacy departments must adapt to new policies and assessment criteria, which may lead to further challenges in drug management and patient care [30].

对于患者和医院双方，新政策会带来哪些经济或就医流程上的变化？今日，记者采访了试点医院之一北 京清华长庚医院的相关负责人，对此进行了解答。 关注1：哪些群体在政策范围内？ 排上了择期手术，住院之前就可开展检查，且相关费用可纳入住院费用结算——近日，北京市医疗保障 局发布了开展"预住院"费用医保支付试点工作的通知，试点将从4月26日起执行。 通知指出，试点医疗机构范围由北京市医疗保险事务管理中心确定。新京报记者从多位业内人士处了解 到，本次有5家综合医院参与了试点。 关注3：哪些病种纳入试点？ 据规定，"预住院"病种范围包括诊断明确、病情相对稳定且经评估符合住院指征行择期手术的病种。具 体病种范围由试点医疗机构自行制定。 "这个政策主要针对择期手术的患者，他们术前发生的一系列相关费用，虽然在门诊执行，但可以转到 住院费用中，以住院的医保支付比例进行报销。"北京清华长庚医院医事科科长张燕向新京报记者介 绍。 根据北京市医保局的通知，北京市基本医疗保险定点医疗机构，在保障医疗质量安全的前提下，对诊断 明确、病情相对稳定且经评估符合住院指征行择期手术的参保人员，通过办理"预住院"完成术前检查检 验，相关费用待参保人员正 ...

Group 1 - Yilida plans to repurchase shares worth 30 to 50 million yuan for employee stock ownership plans, with a maximum price of 6.5 yuan per share [1] - Yinglian shares two major shareholders plan to reduce their holdings by up to 5% [1][2] - Zhongbing Hongjian reports a net loss of 327 million yuan for 2024, with a revenue decline of 25.29% [2][3] Group 2 - Zhongke Electric reports a net profit increase of 626.56% for 2024, with a revenue growth of 13.72% [3][4] - Yong'an Futures reports a net profit decline of 21.07% for 2024, with a revenue decrease of 8.76% [5][6] - Yongjie New Materials reports a net profit increase of 34.28% for 2024, with a revenue growth of 24.71% [7][8] Group 3 - Xibu Securities reports a net profit increase of 20.38% for 2024, despite a revenue decline of 2.64% [9][10] - Jinying Heavy Industry reports a net profit decline of 35.54% for 2024, with a slight revenue increase of 1.13% [10][11] - Haineng Industry reports a net profit decline of 40.45% for 2024, despite a revenue growth of 16.26% [12][13] Group 4 - Penghui Energy reports a net loss of 252 million yuan for 2024, with a revenue increase of 14.83% [14][15] - Weiming Pharmaceutical reports a net loss of 137 million yuan for 2024, with a revenue decline of 16.14% [16][17] - Huachang Technology reports a net profit increase of 184.26% for 2024, with a revenue growth of 6.74% [18][19] Group 5 - Ancar Detection reports a net loss of 213 million yuan for 2024, with a revenue decline of 3.05% [20][21] - Saiwei Intelligent reports a net loss of 507 million yuan for 2024, with a significant revenue decline of 68.03% [22][23] - Qinglong Pipe Industry reports a net profit increase of 976.43% for 2024, with a revenue growth of 36.71% [24][25] Group 6 - Huayin Electric reports a net loss of 113 million yuan for 2024, with a revenue decline of 16.00% [26][27] - Zhongqi New Materials reports a net profit decline of 61.59% for 2024, with a revenue decrease of 22.88% [28][29] - Guangzheng Eye Hospital reports a net loss of 175 million yuan for 2024, with a revenue decline of 16.94% [30][31] Group 7 - Zhenlan Instrument reports a net profit increase of 2.16% for 2024, with a revenue growth of 11.63% [32][33] - Zaiseng Technology reports a net profit increase of 137.99% for 2024, despite a revenue decline of 10.87% [34][35] - Haitai High-tech reports a net profit increase of 51.34% for 2024, with a revenue growth of 25.26% [36][37] Group 8 - Runze Technology reports a net profit increase of 1.62% for 2024, with a revenue growth of 0.32% [38][39]

�� "태백 홈페 블로그램 클립 클로드 클로드 클로드 클로드 클로드 클로드 BB 입 © �� 2023年11월로드립트로드립트로드립트를밀리트립트로드립트롤로드립트롤로드립트롤로드립트레일랜드레일랜드셀러셀램프레드로프로필드트렌트홀덤트롤러블로그램트렌트홀덤슬 ��� �� �����1:397 �� "租车租赁招聘 ...

华夏时报（www.chinatimes.net.cn）记者 于娜 北京报道 "我们医院目前正常接诊，没有变化。"北京三博脑科医院的一位内部人员告诉《华夏时报》记者。对于董事长张 阳被留置、立案调查一事给公司经营及控制权带来的影响等问题，《华夏时报》记者联系采访三博脑科，截至发 稿未收到回复。 民营医院大佬"落马" 公开资料显示，张阳于1965年10月出生，高级工商管理专业，硕士研究生学历。2003年，张阳与北京天坛医院三 位博士生导师共同创立了三博脑科。 三博脑科注册地为北京市海淀区，主要从事以神经专科为特色的临床医疗服务，主要产品包括医疗服务、药品、 供应链、其他业务。目前，三博脑科在北京、重庆、昆明、福建、成都和河南共运营了8家医院。 张阳于2004年至2025年3月，任三博脑科总经理；2014年至今，任三博脑科董事长。同时，张阳担任中国非公立医 疗机构协会副会长、中国医院协会民营医院管理分会副会长、北京市非公立医疗机构协会终身名誉会长。 据2024年年报披露，张阳直接持有公司股份10.59%，与于春江、栾国明、石祥恩为一致行动人，构成对公司的共 同控制。公司2023年4月27日公告的《招股说明书》披露了 ...

文/西风 4月21日晚上，三博脑科医院管理集团股份有限公司（301293）公告：现收到内蒙古自 治区监察委员会签发关于公司控股股东、实际控制人之一暨董事长张阳先生 个人的《留置通知书》和《立案通知书》。张阳先生1965年10月出生，如今已近60岁，现任公司董事长，中国非公立医疗机构协会副会长、中国医院协会民营医 院管理分会副会长、北京市非公立医疗机构协会终身名誉会长。三博脑科2023年5月5日上市，上市未满2年，实控人兼董事长被留置、立案调查了！ 公司注册地北京市海淀区，主要从事以神经专科为特色的临床医疗服务，目前在北京、重庆、昆明、福建、成都和河南共运营了8家医院。 2022年、2023年、2024年，公司分别实现营业收入10.70亿元、13.13亿元、14.29亿元，扣非归母净利润分别为0.5207亿元、0.9360亿元、0.9431亿元。 | 财务指标 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | | --- | --- | --- | --- | --- | --- | | 审计意见 | | | 标准无保留意见 | ...

经济观察报记者张铃 2023年5月，三博脑科上市，目前，其总市值为93亿元。据三博脑科2024年年报，目前其共运营了8家医 院，分别位于北京、重庆、昆明、福建、成都和河南。三博脑科未在此次对张阳实施留置的内蒙古自治 区运营医院。 三博脑科上市后不久，张阳在接受经济观察报专访时提到，三博脑科不收患者红包，不靠药品耗材增加 收入，摒弃各种暗箱操作，每年拒收的红包数额达数百万元，同时给到医生高于公立医院的阳光收入。 2025年3月4日，三博脑科发布公告称，根据其经营发展及管理需要，张阳辞去总经理职务，仍担任董 事、董事长及董事会战略委员会主任委员职务。 4月21日晚，三博脑科（301293）(301293.SZ)公告称，其收到内蒙古自治区监察委员会签发的关于其控 股股东、实际控制人之一暨董事长张阳的个人《留置通知书》和《立案通知书》。 经济观察报记者致电张阳个人手机，显示已关机。他最新的朋友圈更新于4月16日，内容是他转发的家 乡某视频号对他的采访。 4月21日晚，三博脑科多名内部人士告诉经济观察报，他们是在看到公告后才知晓张阳被留置的消息， 他们对此消息感到意外。其中一名内部人士说："就在前两天，他还接受了央媒采 ...

Core Viewpoint - Peking University First Hospital (referred to as "PKU Hospital") is launching the construction of fertility-friendly and child-friendly hospitals, aligning with national policies to support maternal and child health and contribute to a fertility-friendly society [1][4] Group 1: Hospital Initiatives - PKU Hospital is one of the first "mother-baby friendly hospitals" in Beijing, establishing specialized centers for reproductive medicine and pediatrics to enhance maternal and child health services [2] - In 2024, PKU Hospital treated 786,000 women and children, with 65% of pediatric inpatient cases being critical, and recorded 6,614 deliveries, with 95% being high-risk pregnancies [2] - The hospital has implemented an integrated delivery room (LDR) model to provide comprehensive services from labor to postpartum care, ensuring safety and privacy for mothers and infants [2] Group 2: Child-Centric Facilities - The Children's Medical Center at PKU Hospital has expanded its outpatient and inpatient facilities, increasing the pediatric outpatient area by approximately 11.93 times to 9,973 square meters [3] - The center features child-friendly amenities such as play areas, reading corners, and specialized facilities to enhance the hospital experience for children [3] - PKU Hospital has improved its neonatal rescue capabilities, achieving a success rate of over 95% in neonatal intensive care, and has established a 24-hour referral hotline for critical cases [3] Group 3: Strategic Development - To effectively advance the construction of fertility-friendly and child-friendly hospitals, PKU Hospital has developed an implementation plan and formed specialized working groups to ensure efficient and orderly progress [4] - The recent conference marks a significant step in enhancing services tailored to the health needs of women and children, aiming to create a more efficient, safe, and warm healthcare environment [4]

荣军优抚医院担负着集中供养重残、康疗重病等优抚对象的重要职能任务，是国家尊崇尊重退役军人和其他优抚对象的直接体现。辽宁省第二荣军优抚 医院隶属于省退役军人事务厅，始建于1947年，1953年抗美援朝战争结束后落户于丹东五龙背镇，为公益一类事业单位、二级康复专科医院，主要承担 全省1-4级伤残军人集中供养，全省在乡伤残军人定期康复治疗，全省优抚对象医疗巡诊业务，养老服务和培训等职能。 2023年10月，省第二荣军优抚医院从省卫生健康部门转隶以来，全面落实退役军人事务部对优抚医院改革发展的要求，牢固树立"关爱荣军、服务社 会"理念，积极服务备战打仗，为优抚对象竭力保障，为驻地群众精心服务，持续提升医疗水平和服务质量。今年年初，为深入贯彻落实退役军人事务 部等8部门《关于推进优抚医院改革发展的意见》，鼓励引导高素质医疗人才向优抚医院流动，医院本着"请进来，走出去"的人才培养思路，着眼更好 满足残疾退役军人等优抚对象供养和医疗需求，积极开设人才招聘引进绿色通道，邀请辽宁省名中医李国信团队在医院建立名中医工作室，改变以往优 抚医院中医名专家相对缺乏的现状，合力打造"省内知名中医专家定期巡诊、院内优秀专家常年坐诊"的医疗 ...

研究显示，亚太地区的医院经历了从稳步扩张、大流行冲击、上坡恢复到持续增长等阶段。在每个阶段， 我们都分析了医院收入、手术数量和病床占用率与 GDP 同比增长率的关系。 在新冠之前，该地区的医院通过收购和提供更多服务不断扩张。这使得医院收入稳定增长5%至10%，手 术数量增长 10%至 15%，病床占用率稳定在65%至70%，与该地区 4%至 5%的 GDP 增长率保持一致。 尽管医院规模稳步扩大，但大流行病暴露了医院系统的严重弱点，导致收入减少，病床占用率因可用病床 短缺而上升。手术也被推迟或取消，因为病人为了尽量减少接触病毒的风险而回避医院。 后新冠时代，虽然没有了集中性的疾病冲击，医院正面临着一系列趋势和挑战。为了解整个亚太地区目前 的医院经营环境，科尔尼公司在 2022 年至 2024年期间调研了25位医院高管和150多位患者。 与此同时，运营更加灵活的医院能够迅速做出调整。例如，新加坡陈笃生医院（Tan Tock Seng Hospital） 将膝关节置换手术转变为采用增强型术后恢复（ERAS）模式的非卧床手术，将住院时间从六天缩短为一 天。 随着疫苗接种率超过人口的40%，选择性手术出现反弹，到 2 ...